Professor, Medicine, Boston University School of Medicine
Hematology
Vaishali H. Sanchorawala, MB
|
|
Give Review
Vaishali H. Sanchorawala, MB practices Hematology. She attended UMDNJ-New Jersey Medical School. She has 1 awards "Super Doctor". Vaishali H. Sanchorawala, MB is also a published doctor. She has 77 paper published. The most recent paper is: Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. She is registered with Medicare.
Publications
- Clinical presentation and treatment responses in IgM-related AL amyloidosis.
- Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis.
- Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed Systemic AL amyloidosis.
- Lymphadenopathy as a manifestation of amyloidosis: a case series.
- Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.
- Plerixafor-augmented peripheral blood stem Cell mobilization in AL amyloidosis with cardiac involvement: a case series.
- Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis.
- Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
- Simultaneous presentation of kappa-restricted chronic lymphocytic Leukemia and lambda light chain AL amyloidosis.
- New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-Cell tr...
- Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk Myeloma: analysis of SWOG trial S0115.
- Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.
- Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.
- A solitary Mediastinal mass due to localized AL amyloidosis: case report and review of the literature.
- Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.
- Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem Cell transplantation for the treatment of light chain amyloidosis.
- Amyloid Deposits in the Bone Marrow of Patients with Amyloid Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment.
- Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review.
- AL amyloidosis: who, what, when, why, and where.
- Persistent pleural effusions in primary Systemic amyloidosis: etiology and prognosis.
- Incidence and outcome of Acute renal failure complicating autologous stem cell transplantation for AL amyloidosis.
- Outcome of AL amyloidosis after high-dose melphalan and autologous stem Cell transplantation: long-term results in a series of 421 patients.
- Cardiac amyloidosis: evolving approach to diagnosis and management.
- Bortezomib and high-dose melphalan conditioning for stem Cell transplantation for AL amyloidosis: a pilot study.
- Amyloidotic cardiomyopathy: multidisciplinary approach to diagnosis and treatment.
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed Systemic AL amyloidosis: results of a phase 1/2 study.
- Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review.
- Localized amyloidosis of the Breast: a case series.
- Macroglossia - not always AL amyloidosis.
- Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
- Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis.
- High-dose intravenous melphalan with autologous stem Cell transplantation in AL amyloidosis-associated end-stage renal disease.
- Low-dose continuous oral melphalan for the treatment of primary Systemic (AL) amyloidosis.
- Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem Cell transplantation.
- High-dose melphalan and autologous stem-Cell transplantation in patients with AL amyloidosis: an 8-year study.
- Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
- Diaphragm paralysis in primary Systemic amyloidosis.
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amy...
- Association of acquired von Willebrand syndrome with AL amyloidosis.
- Adapting to AL amyloidosis.
- Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
- Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem Cell transplantation in patients over age 65.
- Azotemia associated with use of lenalidomide in plasma Cell dyscrasias.
- An overview of high-dose melphalan and stem Cell transplantation in the treatment of AL amyloidosis.
- A case of atypical light chain deposition Disease--diagnosis and treatment.
- Light-chain (AL) amyloidosis: diagnosis and treatment.
- Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-Cell transplantation.
- Short and long-term outcome of treatment with high-dose melphalan and stem Cell transplantation for multiple myeloma-associated AL amyloidosis.
- Weekly and twice-weekly bortezomib in patients with Systemic AL amyloidosis: results of a phase 1 dose-escalation study.
- Hepatic response after high-dose melphalan and stem Cell transplantation in patients with AL amyloidosis associated liver disease.
- Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
- Cardiac transplantation followed by dose-intensive melphalan and autologous stem-Cell transplantation for light chain amyloidosis and heart failure.
- Kidney dysfunction during lenalidomide treatment for AL amyloidosis.
- Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem Cell transplantation: a ca...
- Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem Cell transplantation.
- Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ''melphalan recall'' reaction.
- Tandem cycles of high-dose melphalan and autologous stem Cell transplantation increases the response rate in AL amyloidosis.
- Clinical and molecular characteristics of patients with non-amyloid light chain deposition Disorders, and outcome following treatment with high-dose melphalan and auto...
- AL amyloidosis associated with B-Cell lymphoproliferative disorders: frequency and treatment outcomes.
- Serum free light-chain responses after high-dose intravenous melphalan and autologous stem Cell transplantation for AL (primary) amyloidosis.
- Predictive factors for hematopoietic engraftment after autologous peripheral blood stem Cell transplantation for AL amyloidosis.
- High-dose intravenous melphalan and autologous stem Cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloi...
- Spontaneous rupture of the spleen in AL amyloidosis.
- Immunologic recovery after autologous blood stem Cell transplantation in patients with AL-amyloidosis.
- An overview of the use of high-dose melphalan with autologous stem Cell transplantation for the treatment of AL amyloidosis.
- Effect of dose-intensive intravenous melphalan and autologous blood stem-Cell transplantation on al amyloidosis-associated renal disease.
- Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
- Intermediate-dose intravenous melphalan and blood stem Cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis.
- Dose-intensive melphalan with blood stem-Cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
- Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.
- A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
- High-dose melphalan and autologous stem Cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution.
- Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
- Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
- Amyloidomics comes of age.
- Regression of cardiac wall thickness following chemotherapy and stem Cell transplantation for light chain (AL) amyloidosis.
Schools
University of MumbaiKing Edward Memorial Hospital And Seth Gordhandas Sunderdas Medical College
UMDNJ Nj Med School
Boston University Med Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Aortic Embolism and Thrombosis
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
UMDNJ-New Jersey Medical School -
Seth G.S. Medical College
Hospital
-
Boston Medical Center
Drug Facts
| NPI NUMBER | 1003886573 | |
| NPPES Provider LastName | SANCHORAWALA | |
| NPPES Provider FirstName | VAISHALI | |
| NPPES Provider ZIPCode | 021182905 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 212.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 6.13 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003886573 |
| Last Name Of The Provider | SANCHORAWALA |
| First Name Of The Provider | VAISHALI |
| View All |
Similar Doctors
|
|
Dr. Katayoon Goodarzi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Ilene A. Galinsky |
|
|
Dr. Syed S. Mahmood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hsiu-Hung Wang, MD |
|
|
Joan Sully, NP |
|
|
Dr. Adam S. Crystal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meghan E. Shea, MD |
|
|
Dr. Othon Iliopoulos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ayad Hamdan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oreofe O. Odejide, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Birrer, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Daniel C. Cho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Goldstein, MD |